Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877698 | 0.72 | ALDH1A1 (1.00) | ALDH1A1TSHRCASP1 | |
| SCHEMBL22296005 | 0.70 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL20712762 | 0.70 | — | — | |
| SCHEMBL24249016 | 0.70 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL16414228 | 0.70 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL24875618 | 0.69 | — | — | |
| SCHEMBL14033220 | 0.69 | — | — | |
| SCHEMBL4278112 | 0.68 | ALDH1A1 (0.67) | ALDH1A1TSHRCASP1 | |
| SCHEMBL12942889 | 0.67 | — | — | |
| SCHEMBL31194820 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11021708-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200224199-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | ALDH1A1 4181/4885TSHR 4288/4885CASP1 3456/4885 |
| US-11021708-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | ALDH1A1 4181/4885TSHR 4288/4885CASP1 3456/4885 |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | ALDH1A1 4181/4885TSHR 4288/4885CASP1 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.